Improving drug delivery to brain tumors using new compounds
ENHANCEMENT OF BBB CROSSING OF AR DEGRADERS IN GBM
This study is looking at a new treatment for glioblastoma, a tough brain tumor, by testing small molecules that can help break down a protein that often makes the tumor worse, especially in men, to see if they work better than the usual chemotherapy.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland State University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11040457 on NIH RePORTER |
What this research studies
This research focuses on glioblastoma (GBM), a highly aggressive brain tumor with a poor prognosis. The team is investigating a new class of small molecules designed to degrade the androgen receptor, which is overexpressed in many GBM cases, particularly in male patients. By enhancing the ability of these compounds to cross the blood-brain barrier, they aim to improve treatment outcomes compared to the current standard chemotherapy, Temozolomide. The research includes testing these compounds in patient-derived models to assess their effectiveness and safety.
Who could benefit from this research
Good fit: Ideal candidates for this research are adult patients diagnosed with glioblastoma, particularly those who have shown resistance to standard treatments.
Not a fit: Patients with glioblastoma who are not eligible for experimental therapies or those with other significant health issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially improving survival rates and quality of life for patients.
How similar studies have performed: While the approach of using androgen receptor degraders is relatively novel, similar strategies targeting the blood-brain barrier have shown promise in other cancer treatments.
Where this research is happening
Cleveland, United States
- Cleveland State University — Cleveland, United States (Active)
Researchers
- Principal investigator: Su, Bin — Cleveland State University
- Study coordinator: Su, Bin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.